ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1315

Gene Expression Profiling and Pathway Changes Associated with Clinical Response to Tabalumab Blockade of Membrane Bound and Soluble B Cell Activating Factor in Rheumatoid Arthritis

Wendy J. Komocsar1, Mark C. Genovese2, Ernst R. Dow3, Poulabi Banerjee1, Michelle A. Penny3, Eric P. Nantz1, Sergey Stepaniants4, Anne Ho4, Pierre-Yves Berclaz1 and Robert W. Hoffman1, 1Eli Lilly and Company, Indianapolis, IN, 2Division of Rheumatology, Stanford University, Palo Alto, CA, 3Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 4Covance Genomics Laboratory LLC, Seattle, WA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: genomics and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Tabalumab, a monoclonal antibody neutralizing membrane bound and soluble B cell activating Factor (BAFF), has been shown to reduce the signs and symptoms of rheumatoid arthritis (RA)1 . To better define tabalumab’s molecular mechanism of action, gene expression profiling of whole blood RNA was performed to characterize individual gene expression signatures and to map the associated pathways involved with BAFF blockage in RA.

Methods: Whole blood RNA was obtained from 158 RA subjects with inadequate response to methotrexate enrolled in a phase 2 randomized trial in which patients received subcutaneous placebo,  1, 3, 10, 30, 60 or 120 mg of tabalumab  every 4 weeks (wks) over 24 wks.  At total of 669 RNA samples were obtained at baseline, wk  1, 4 and 16, and follow up visits at wk 32 and 44. Samples from 30 healthy blood donors controls were analyzed. Affymetrix U133 Plus 2.0 expression arrays were used to measure gene expression. Data were normalized using Robust Multichip Average (RMA) algorithm2. Following quality analysis a total of 676 samples were profiled. B cells from peripheral blood were enumerated using flow cytometry. Total serum IgG, A and M, rheumatoid factor (RF) and ACPA were measured using nepholometry. Statistical analyses were performed using a mixed effect model and p-values were adjusted for multiple hypotheses testing using False Discovery Rate (FDR) and Bonferroni techniques. Paired t-tests were used to generate a list of biologically relevant genes whose transcripts exhibited consistent changes in response to tabalumab treatment.

Results: The genes demonstrating significant changes with treatment over time are listed in the table. Many of these genes are represented by multiple probe sets. Most were down regulated . Several of these have been previously reported to be associated with RA susceptibility. The use of gene ontology, pathway and literature mining revealed that the most significant changes were related to B cell development and signaling. Changes in CD19 expression were correlated with CD19 enumeration. Additional genes related to B cell development and signaling were associated with changes in CD19 expression. Consistent with these changes, serum immunoglobulins IgM, IgA decreased significantly from baseline and IgG had a numerical decrease over time.  There were no statistically significant changes in RF or ACPA levels from baseline.

Conclusion:

Using RNA gene expression profiling and pathway analysis, significant gene changes associated with the clinical response to tabalumab were identified. We observed changes in genes related to B cell development and maturation which is consistent with tabalumab’s mechanism of action. These data may provide additional potential targets or biomarkers for future studies in RA.  

1. Genovese et al. Ann Rheum Dis 2011;70(Suppl3):71

2. Irizarry et al, (2003)Nucleic Acids Research2003 31(4):e15

Table  Top candidate genes whose gene expression changes were significant following treatment with tabalumab

Gene

Raw p-value/ Multiplicity Adjusted p-value

Gene

Raw p-value/ Multiplicity Adjusted p-value

T-cell leukemia/lymphoma 1A, TCL1A

5.40E-18  /

2.90E-13

phosphatidic acid phosphatase type 2 domain containing 1B, PPAPDC1B

6.00E-08 /

3.30E-03

MACRO domain containing 2, MACROD2

2.90E-09 /

1.60E-04

like-glycosyltransferase, LARGE

1.70E-10 /

9.10E-06

immunoglobulin heavy constant delta, IGHD

1.90E-10  /

1.00E-05

ATP-binding cassette, sub-family B (MDR/TAP), member 4, ABCB4

3.00E-10  /

1.60E-05

CD72 molecule, CD72

1.70E-09  /

9.20E-05

immunoglobulin heavy constant mu, IGHM

2.10E-09  /

1.10E-04

chronic lymphocytic leukemia up-regulated 1, CLLU1

3.20E-09 /

1.70E-04

sodium channel, voltage-gated, type III, alpha subunit, SCN3A

1.10E-08 /

5.80E-04

Fc receptor-like A, FCRLA

7.4 E-08 /

4 E-08

major histocompatibility complex, class II, DO beta, HLA-DOB

4.30E-08 /

2.30E-03

tetraspan 13, TSPAN13

4.30E-08  /

2.30E-03

CD79a molecule, CD79A

3.20E-07  /

9.20E-04

CD19 molecule, CD19

4.80E-07 /

1.20E-03

family with sequence similarity 129, member C, FAM129C

4.60E-07 /

1.20E-03

Fc fragment of IgE, low affinity II, receptor for (CD23), FCER2

1.10E-06 /

2.30E-03

protein kinase (cAMP-dependent, catalytic) inhibitor gamma, PKIG

7.30E-07 /

1.70E-03

CD200 molecule, CD200

9.80E-07 /

2.20E-03

sorting nexin 22, SNX22

6.70E-07  /

1.70E-03

coronin, actin binding protein, 2B, CORO2B

1.10 E-06 / 4.90 E-03

Fc receptor-like 2, FCRL2

2.40E-06 /

5.30E-03

probe 243780_at near the BAFF Receptor, BAFF-R

2.90E-06  /

5.50E-03

Fc receptor-like 1, FCR1

3.50E-06  /

6.30E-03


Disclosure:

W. J. Komocsar,

Eli Lilly and Company,

1,

Eli Lilly and Company,

3;

M. C. Genovese,

Eli Lilly and Company,

2,

Eli Lilly and Company,

5;

E. R. Dow,

Eli Lilly and Company,

1,

Eli Lilly and Company,

3;

P. Banerjee,

Eli Lilly and Company,

1,

Eli Lilly and Company,

3;

M. A. Penny,

Eli Lilly and Company,

1,

Eli Lilly and Company,

3;

E. P. Nantz,

Eli Lilly and Company,

1,

Eli Lilly and Company,

3;

S. Stepaniants,

Eli Lilly and Company,

9;

A. Ho,

Eli Lilly and Company,

9;

P. Y. Berclaz,

Eli Lilly and Company,

1,

Eli Lilly and Company,

3;

R. W. Hoffman,

Eli Lilly and Company,

1,

Eli Lilly and Company,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gene-expression-profiling-and-pathway-changes-associated-with-clinical-response-to-tabalumab-blockade-of-membrane-bound-and-soluble-b-cell-activating-factor-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology